Ceruvia Lifesciences has submitted an FDA Investigational New Drug (IND) Application for its NYPRG-101 Migraine Prevention Program.
In 1943, Swiss chemist Albert Hofmann took the first LSD trip – what is it looking like for the compound today?
Freedom to Operate has published its new study that can be used to fight back against anyone attempting to patent a polymorphic form of LSD and...
Findings from a study comparing the acute effects of the two compounds suggest that 20 mg psilocybin is equivalent to 100 μg LSD, and 30 mg...
A recent study testing the impact of microdosing LSD has suggested the practice has no therapeutic or cognitive effects.
A group of scientists have reported findings that provide a foundation for the structure-based design of safe and effective non-hallucinogenic, rapid-acting antidepressants.
A new narrative review of systematic evidence has been published by leading researchers at Drug Science to get the facts on the adverse effects of classic...
MindMed is expected to begin enrolling patients immediately into its proof-of-concept exploratory trial for the use of LSD to treat adult ADHD.
BetterLife Pharma has announced its first set of positive data showing the anti-depressant effects of an LSD derivative – 2-bromo-LSD (TD-0148A).
A new study has been launched to investigate the effects of LSD microdosing on sleep and cognitive measures.